ClinicalTrials.gg
RecruitingNCT07856472AI-CVDUpdated Oct 2, 2026

AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study

An observational study in Cardiovascular Diseases, Coronary Artery Disease and Heart Failure, sponsored by Inha University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Inha University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.

Read the detailed description

Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality. Standard 12-lead ECGs are widely accessible tools for cardiovascular screening and diagnosis; however, traditional visual interpretations have limitations. Recent advancements in deep learning offer unprecedented performance in extracting hidden patterns from ECG signals.

This study is a retrospective, multicenter investigation conducted across multiple tertiary medical centers in South Korea. The primary objectives are:

  • To extract and encrypt raw 12-lead ECG data (XML format) into binary datasets to ensure patient privacy and data standardization.
  • To advance and validate deep neural network models-specifically combining Bi-LSTM and attention mechanisms-for diagnosing conditions such as coronary artery disease, heart failure, and related structural heart diseases.
  • To assess the clinical utility and prognostic performance of AI-ECG risk prediction models in real-world cohorts spanning data from 2005 to 2022.
02

Conditions studied

  • Cardiovascular Diseases
  • Coronary Artery Disease
  • Heart Failure
  • Atrial Fibrillation (AF)
  • Ventricular Hypertrophy

Keywords

  • Artificial Intelligence
  • Electrocardiogram
  • Deep Learning
  • Multicenter Study
  • Retrospective Study
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients visiting the participating tertiary hospitals with extractable electrocardiogram records and diagnosed with cardiovascular diseases.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older diagnosed with cardiovascular diseases, including coronary artery disease and heart failure.
  • Patients with 12-lead (ECG) records extractable as text (XML

Exclusion criteria

Exclusion Criteria:

- Patients deemed inappropriate as study subjects by the investigator's judgment

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Cardiovascular Disease Cohort

    Patients aged 18 years or older diagnosed with cardiovascular diseases, including coronary artery disease and heart failure, who have extractable text-format (XML) 12-lead electrocardiogram records.

    Other: Retrospective ECG Data Analysis

Interventions

  • OtherRetrospective ECG Data Analysis

    Analysis of de-identified 12-lead electrocardiogram raw data using deep learning models for cardiovascular disease diagnosis and prognosis.

06

What researchers measure

Primary outcomes

  1. Diagnostic Performance (AUC-ROC) of AI-ECG Models

    To evaluate the area under the receiver operating characteristic curve (AUC-ROC) of the deep neural network-based 12-lead ECG model for diagnosing cardiovascular diseases compared to reference clinical standards.

    Time frame: Baseline

Secondary outcomes

  1. Sensitivity and Specificity of AI-ECG Models

    To evaluate the association between AI-ECG risk scores and long-term clinical outcomes, including all-cause mortality and heart failure-related hospitalizations.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data are not available due to institutional policy and patient privacy regulations regarding retrospective clinical records.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 60 months is below that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Mar 1, 2023
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856472
Lead sponsor
Inha University Hospital
Responsible party
Yong-Soo Baek (Professor, Inha University Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Mar 1, 2023
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Yongsoo Baek, MD, PhD
Contact
existsoo@inha.ac.kr
+82-32-890-2200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion